Beactica Therapeutics

Beactica Therapeutics is a privately held biotechnology company that develops novel small molecule therapeutics for genetically defined, life-threatening cancers. Its discovery efforts span allosteric modulators, protein-protein interaction inhibitors, and targeted protein degraders generated through its proprietary Eclipsor platform.

The company's lead programmes include BEA-17, a first-in-class LSD1-CoREST degrader with FDA Orphan Drug Designation for glioblastoma, and P65-047, a first-in-class TEAD transcription factor degrader for Hippo pathway-driven cancers. Beactica also conducts selective drug discovery partnerships with pharmaceutical and academic partners, including KU Leuven, NIH/NCATS, and BioArctic.